On 17 June 2026, Dingdang Health Technology Group Ltd. filed a Next Day Disclosure Return detailing recent capital movements and share-repurchase activity.

Issued share capital • The company’s issued share count remained unchanged at 1,254.65 million ordinary shares between the opening balance on 16 June 2026 and the close of 17 June 2026. • No treasury shares were outstanding.

Repurchase programme (19 May–17 June 2026) • Dingdang Health bought back 9.76 million shares for cancellation, equal to approximately 0.78 % of the current issued share capital. • The aggregate consideration amounted to HK$8.79 million, implying a volume-weighted average repurchase price of HK$0.90 per share. Transaction prices ranged from HK$0.83 to HK$0.96. • The latest daily purchase, executed on 17 June 2026, involved 603,000 shares at prices between HK$0.92 and HK$0.95, costing HK$0.57 million.

Repurchase mandate utilisation • Since the mandate was granted on 28 May 2025, the company has repurchased 74.58 million shares, representing 56.55 % of the 131.95 million shares authorised for buy-back and 5.65 % of the shares outstanding on the mandate date. • In line with Hong Kong Listing Rules, Dingdang Health is subject to a 30-day moratorium on new share issues or treasury share sales until 17 July 2026.

All repurchases were executed on the Hong Kong Stock Exchange and, according to the company, complied with applicable regulations and board authorisation.